USSTOCK.TODAY
Market Closed
Log in Sign up

UBS Analyst Classifies Novo Nordisk as Value Trap

Nasdaq +1 ·

NVO Novo Nordisk ADR
$38.18 -0.21%
View chart & analysis →
  1. 1UBS analyst Michael Lee stated a preference for Eli Lilly in a recent conversation with CNBC.
  2. 2Michael Lee called Novo Nordisk a value trap.
  3. 3With Novo Nordisk recording a change of -0.21% today, its dividend yield is 4.70%.

So what's the key point?

A UBS analyst said Eli Lilly is a better option than Novo Nordisk. This means that while Novo Nordisk's stock price may look cheap, it could actually be risky.

Source Nasdaq +1 · View original ↗

Related 3-line summaries

Comparison of Eli Lilly and Novo Nordisk FY2025 Results Nasdaq +2 · 2d agoBloom Energy shares fall; UBS raises price target to $350 Stocktwits +2 · 2h agoSamsung Electronics completes quality verification for NVIDIA's next-generation HBM4E InvestorsHub +1 · 2h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news